Form 10-Q ZS Pharma, Inc. For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
ZS Pharma (ZSPH) Misses Q3 EPS by 7c
November 10, 2014 5:03 PM ESTZS Pharma (NASDAQ: ZSPH) reported Q3 EPS of ($0.81), $0.07 worse than the analyst estimate of ($0.74).
For earnings history and earnings-related data on ZS Pharma (ZSPH) click here.
... More